A Case of Rituximab-Induced Necrotizing Fasciitis and a Review of the Literature.
Abdullateef AbdulkareemRyan S D'SouzaOluwaseun ShogbesanAnthony A DonatoPublished in: Case reports in hematology (2017)
Necrotizing fasciitis is a fulminant soft tissue infection characterized by rapid progression and high mortality. Rituximab is a generally well-tolerated immunosuppresive medication used for B-cell malignancies and some rheumatological disorders. We report a case of a 69-year-old male with chronic lymphocytic leukemia who suffered necrotizing fasciitis of his left lower extremity secondary to Clostridium septicum 7 weeks after treatment with rituximab. Despite immediate intravenous antimicrobial therapy and emergent fasciotomy with extensive debridement, his hospital course was complicated by septic shock and he required an above-the-knee amputation. Physicians need to be aware of the possibility of necrotizing fasciitis in patients presenting with skin infections after rituximab therapy.
Keyphrases
- chronic lymphocytic leukemia
- soft tissue
- diffuse large b cell lymphoma
- septic shock
- hodgkin lymphoma
- healthcare
- primary care
- total knee arthroplasty
- adverse drug
- high glucose
- high dose
- cardiovascular events
- stem cells
- knee osteoarthritis
- oxidative stress
- cardiovascular disease
- diabetic rats
- emergency department
- gestational age
- endothelial cells
- hepatitis b virus
- lower limb
- bone marrow
- replacement therapy
- cell therapy